Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a serial prospective cross-sectional nationwide study of residual samples (March – October 2020)
Authors:
- Sereina HerzogSHSereina Herzog
- Jessie De BieJBJessie De Bie
- Steven AbramsSASteven Abrams
- Ine WoutersIWIne Wouters
- Esra EkinciEEEsra Ekinci
- Lisbeth PatteetLPLisbeth Patteet
- Astrid CoppensACAstrid Coppens
- Sandy De SpiegeleerSSSandy De Spiegeleer
- Philippe BeutelsPBPhilippe Beutels
- Pierre Van DammePDPierre Van Damme
- Niel HensNHNiel Hens
- Heidi TheetenHTHeidi Theeten
Preprint
Abstract
To assess the evolving SARS-CoV-2 seroprevalence and seroincidence related to the national lock-down in Belgium, a nationwide seroprevalence study, stratified by age, sex and region using 3000-4000 residual samples was performed during 7 periods between 30 March and 17 October 2020. Residual sera from ambulatory patients were analyzed for IgG antibodies against S1 proteins of SARS-CoV-2 with a semi-quantitative commercial ELISA. Weighted seroprevalence (overall, by age category and sex) and seroincidence during 7 consecutive periods were estimated for the Belgian population while accommodating test-specific sensitivity and specificity. The weighted overall seroprevalence initially increased from 1.8% (95% CrI 1.0-2.6) to 5.3% (95% CrI 4.2-6.4), implying a seroincidence of 3.4% (95% CrI 2.4-4.6) between the 1 st and 2 nd collection period over a period of 3 weeks during the lockdown period (start lockdown mid March 2020). Thereafter, seroprevalence stabilized, however, significant decreases are observed when comparing the 3 rd with the 5 th and also with the 6 th period resulting in negative seroincidence estimates after lockdown was lifted. We estimated for the last collection period mid October 2020 a weighted overall seroprevalence of 4.2% (95% CrI 3.1-5.2). During lockdown, an initial small but increasing fraction of the Belgian population showed serologically detectable signs of exposure to SARS-CoV-2, which did not further increase when confinement measures eased and full lockdown was lifted.Keywords
All Related Versions
- Published version: Eurosurveillance, 27 (9), 2100419.
This publication has 21 references indexed in Scilit:
- SeroTracker: a global SARS-CoV-2 seroprevalence dashboardThe Lancet Infectious Diseases, 2021
- Validation of a commercially available SARS-CoV-2 serological immunoassayClinical Microbiology and Infection, 2020
- Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19New England Journal of Medicine, 2020
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological studyThe Lancet, 2020
- Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based studyThe Lancet, 2020
- Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophagesNature Reviews Immunology, 2020
- Evaluation of nine commercial SARS-CoV-2 immunoassaysmedRxiv, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementationEpidemiology and Infection, 2013